Aarti Pharmalabs is a leading manufacturer of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), serving global pharmaceutical companies. With expertise in complex chemistries and value-added products, the company plays a crucial role in the pharmaceutical supply chain. Aarti Pharmalabs is known for its innovation-driven approach, ensuring high-quality, cost-effective solutions that meet stringent regulatory standards. Leveraging advanced research, robust infrastructure, and a strong commitment to sustainability, the company delivers customised solutions to support drug development and production worldwide. As a trusted partner in the industry, Aarti Pharmalabs continues to expand its global footprint while driving pharmaceutical innovation.
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue (INR Cr) | 1877 -9.4% | 2073 65.6% | 1252 - | 0 - | 0 - |
Net Operating Income (INR Cr) | 1853 -4.76% | 1945 62.11% | 1200 0.00% | 0 0.00% | 0 0.00% |
Profit (INR Cr) | 217 12.1% | 193 58.3% | 122 - | 0 100.0% | 0 - |
Assets (INR Cr) | 2048 15.1% | 1779 3.0% | 1728 - | 0 0.0% | 0 - |
Net Worth (INR Cr) | 1757 12.7% | 1558 12.4% | 1386 - | 0 0.0% | 0 0.0% |
Employee Cost (INR Cr) | 128 5.5% | 121 42.4% | 85 - | 0 - | 0 - |
Interest Cost (INR Cr) | 17 | 21 | 12 | 0 | 0 |
Cash & Bank Balance (INR Cr) | 24 | 12 | 83 | 0 | 0 |
Total Debt (INR Cr) | 285 | 215 | 341 | 0 | 0 |
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Profit As % Of Revenues | 11.6% | 9.3% | 9.8% | - | - |
Profit As % Of Assets | 10.6% | 10.9% | 7.1% | - | - |
Profit As % Of Networth | 12.3% | 12.4% | 8.8% | - | - |
Interest Cost to EBITDA % | 4.5% | 6.2% | 5.8% | - | - |
Debt to Equity Ratio | 0.16 | 0.14 | 0.25 | 0.09 | - |
RONW | 13.1% | 13.1% | 17.6% | - | - |
ROCE | 16.6% | 16.1% | 19.4% | 0.0% | 0.0% |